nmsg

Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO

Nerviano, Italy, May 14, 2014 – Nerviano Medical Sciences has discovered Milciclib, an inhibitor of cyclin-dependent kinase and Src family members, and a limited number of additional kinases. Phase II results of Miciclib in patients with thymic carcinoma will be reported at the 2014 American Society of Clinical Oncology (ASCO) annual meeting.

Presentation title: A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC).
Authors: Besse, B et al.

Meeting: 2014 ASCO Annual Meeting
Abstract No: 7526

Sub-category: Thymic Malignancies
Category: Lung Cancer - Non-Small Cell Local-regional/Small Cell/Other Thoracic Cancers
Session: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Type: Poster Highlights Session

Time 1: Sunday June 1, 8:00 AM to 11:00 AM Location 1: S405
Time 2: Sunday June 1, 11:30 AM to 12:45 PM Location 2: S406

Link to abstract on the conference website: http://abstracts.asco.org/144/AbstView_144_131226.html

 
Per offrirti un'esperienza di navigazione ottimizzata NMS Group e le società controllate utilizzano cookies, anche di terze parti.
Proseguendo con la navigazione acconsenti al loro impiego in conformità della nostra  
Cookie Policy.